Effect of donor availability on outcome in ALL in CR1
| Outcome parameter . | Donor (n = 96) . | No donor (n = 161) . | ||||
|---|---|---|---|---|---|---|
| Total number of events (death; relapse) . | Probability of outcome at 5 y (% ± SE) . | Total number of events (death; relapse) . | Probability of outcome at 5 y (% ± SE) . | P . | Hazard ratio (95% CI) . | |
| All patients | ||||||
| DFS | 37 | 60 ± 5 | 76 | 42 ± 4 | .01 | 0.60 (0.41-0.89) |
| Relapse | 22 | 24 ± 4 | 72 | 55 ± 4 | < .001 | 0.37 (0.23-0.60) |
| NRM | 15 | 16 ± 4 | 4 | 3 ± 1 | .002 | 4.84 (1.60-14.6) |
| Survival | 35 | 61 ± 5 | 67 | 47 ± 5 | .08 | 0.70 (0.46-1.05) |
| Standard risk | 50 patients | 88 patients | ||||
| DFS | 15 | 69 ± 7 | 46 | 45 ± 5 | .007 | 0.47 (0.26-0.84) |
| Relapse | 7 | 14 ± 5 | 44 | 52 ± 5 | < .001 | 0.23 (0.10-0.51) |
| NRM | 8 | 16 ± 5 | 2 | 2 ± 2 | .01 | 5.93 (1.25-28.0) |
| Survival | 15 | 69 ± 7 | 42 | 49 ± 6 | .05 | 0.57 (0.31-1.02) |
| Poor risk | 46 patients | 73 patients | ||||
| DFS | 22 | 50 ± 8 | 30 | 35 ± 7 | .23 | 0.72 (0.41-1.24) |
| Relapse | 15 | 34 ± 7 | 28 | 61 ± 7 | .03 | 0.52 (0.28-0.97) |
| NRM | 7 | 15 ± 7 | 2 | 4 ± 3 | .08 | 3.67 (0.76-17.7) |
| Survival | 20 | 53 ± 8 | 25 | 41 ± 8 | .50 | 0.82 (0.45-1.47) |
| Outcome parameter . | Donor (n = 96) . | No donor (n = 161) . | ||||
|---|---|---|---|---|---|---|
| Total number of events (death; relapse) . | Probability of outcome at 5 y (% ± SE) . | Total number of events (death; relapse) . | Probability of outcome at 5 y (% ± SE) . | P . | Hazard ratio (95% CI) . | |
| All patients | ||||||
| DFS | 37 | 60 ± 5 | 76 | 42 ± 4 | .01 | 0.60 (0.41-0.89) |
| Relapse | 22 | 24 ± 4 | 72 | 55 ± 4 | < .001 | 0.37 (0.23-0.60) |
| NRM | 15 | 16 ± 4 | 4 | 3 ± 1 | .002 | 4.84 (1.60-14.6) |
| Survival | 35 | 61 ± 5 | 67 | 47 ± 5 | .08 | 0.70 (0.46-1.05) |
| Standard risk | 50 patients | 88 patients | ||||
| DFS | 15 | 69 ± 7 | 46 | 45 ± 5 | .007 | 0.47 (0.26-0.84) |
| Relapse | 7 | 14 ± 5 | 44 | 52 ± 5 | < .001 | 0.23 (0.10-0.51) |
| NRM | 8 | 16 ± 5 | 2 | 2 ± 2 | .01 | 5.93 (1.25-28.0) |
| Survival | 15 | 69 ± 7 | 42 | 49 ± 6 | .05 | 0.57 (0.31-1.02) |
| Poor risk | 46 patients | 73 patients | ||||
| DFS | 22 | 50 ± 8 | 30 | 35 ± 7 | .23 | 0.72 (0.41-1.24) |
| Relapse | 15 | 34 ± 7 | 28 | 61 ± 7 | .03 | 0.52 (0.28-0.97) |
| NRM | 7 | 15 ± 7 | 2 | 4 ± 3 | .08 | 3.67 (0.76-17.7) |
| Survival | 20 | 53 ± 8 | 25 | 41 ± 8 | .50 | 0.82 (0.45-1.47) |
HR indicates hazard ratio for donor compared to no donor from univariate Cox model; P value from likelihood ratio test; n, number of patients; DFS, disease-free survival; NRM, nonrelapse mortality; and SE, standard error.
All survival end points are determined from date of evaluation of intensification chemotherapy and presented as probabilities in time. Events are given as (absolute) total numbers of relapse (accounting for DFS and relapse) and/or death (accounting for OS, DFS, and NRM) that had occurred during the time of follow-up.